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Abstract: Efflux pumps of the Resistance Nodulation Division (RND) superfamily play a major role in the intrinsic and 
acquired resistance of Gram-negative pathogens to antibiotics. Moreover, they are largely responsible for multi-drug resis-
tance (MDR) phenomena in these bacteria. The last decade has seen a sharp increase in the number of experimental and 
computational studies aimed at understanding their functional mechanisms. Most of these studies focused on the RND 
drug/proton antiporter AcrB, part of the AcrAB-TolC efflux pump actively recognizing and expelling noxious agents from 
the interior of bacteria. These studies have been focused on the dynamical interactions between AcrB and its substrates 
and inhibitors, on the details of the proton translocation mechanisms, and on the way AcrB assembles with protein part-
ners to build up a functional pump. In this review we summarize these advances focusing on the role of AcrB. 
Keywords: Multi-drug resistance, membrane barrier, efflux pumps, RND transporters, proton motive force, AcrAB-TolC, anti-
biotics, EPIs. 
ANTIBIOTIC RESISTANCE AND THE MEMBRANE 
BARRIER 
The re-emergence of bacterial resistance to known and 
new antimicrobials in the last decades is one of the major 
threats to public health all over the world [1-9]. New and re-
emerging diseases are thought to be responsible for more 
than 13 million deaths worldwide each year [10]. Moreover, 
lethal bacterial strains, strictly confined to nosocomial set-
tings until the recent past, are found these days in the com-
munity with a severe frequency [11, 12]. This is a conse-
quence of several factors.  
First, the intense (ab)use of antibiotics, biocides and her-
bicides begun in the last century has prompted the evolution 
of defense strategies and the selection of resistant strains in a 
wide variety of microorganisms [13-16]. 
Second, despite the recognized need for new antimicro-
bial agents [17, 18], pharmaceutical companies have cut their 
investments in antibiotic development [17, 19-21], and only 
in the last few years a new effort is ongoing in the field of 
antibacterial research [22]. As a result, only a few new 
classes of antibiotics have been brought to market in the last 
30 years, and many companies have left the field [6, 23, 24]. 
Third, in addition to non-scientific concerns, the discovery 
and the development of novel antibacterial agents against 
multi-drug resistance has shown to be one of the most diffi-
cult challenges for the scientific community [25-28]. Tradi- 
 
*Address correspondence to this author at the Department of Physics, Uni-
versity of Cagliari, S.P. 8, km 0.700, 09042 Monserrato (CA), Italy;  
Tel: +390706754847; Fax: +390706753191;  
Email: vargiu@dsf.unica.it 
tional screening protocols having largely failed to address 
the complexity of bacterial resistance, which requires instead 
new and more powerful methods [11, 26, 29-31]. 
In view of these considerations, it is not surprising that 
some pathogenic bacterial strains have acquired today resis-
tance to almost all known antibiotics [32-34]. These phe-
nomena, known as multi, extensive or total (or pan) drug 
resistance (MDR, XDR and TDR (or PDR) respectively, 
depending on how many classes of antibiotics are effective 
in the treatment of the disease [35]), are related to the occur-
rence of specific resistance mechanisms such as target and 
drug modification, and of more general ones which reduce 
the flux of antibiotics to the bacterial cytoplasm, where their 
targets reside [26, 36-38]. The reduction of intracellular drug 
concentration occurs by changes in membrane permeability 
(alterations and/or repression of porin expression), which 
slows down the influx of most drugs [21, 26, 29, 31, 36, 38-
41]. However, this mechanism is not sufficient to explain the 
high levels of resistance found in pathogenic bacteria, and 
the additional contribution of active exporters, the so-called 
efflux pumps, is necessary in order to achieve the character-
istic levels of intrinsic resistance [36, 37, 40, 42-54]. 
The interplay between influx and efflux endows bacteria 
with a general mechanism of resistance that effectively keeps 
the concentration of noxious agents within bacteria at suble-
thal levels. Furthermore, it gives bacteria the opportunity to 
reinforce more specific mechanisms such as enzymatic inac-
tivation and modification of the drug target(s). In view of the 
mechanism behind MDR, it is not surprising that this phe-
nomenon is particularly effective in Gram-negative bacteria, 
where two membranes (inner and outer respectively) enve-
lope the periplasm [55-58]. 
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RND EFFLUX PUMPS OF GRAM-NEGATIVE BAC-
TERIA ARE MAJOR PLAYERS IN MDR: THE AC-
RAB-TOLC PARADIGM 
Among the five superfamilies of efflux pumps, Resis-
tance-Nodulation-cell-Division (RND) superfamily members 
belonging to the HAE1 family (eight families of RND efflux 
pumps have been discovered so far [59]) are the most preva-
lent in multidrug resistant Gram-negative bacteria pheno-
types [44, 48, 58, 60-66]. RND efflux pumps have an estab-
lished role in detoxification of intracellular metabolites, in-
trinsic and acquired resistance, as well as in quorum sensing, 
invasion, adherence and colonization of the host [67-71]. 
The inner-membrane RND components match up with two 
other components, a periplasmic adaptor protein and an outer 
membrane (OM) channel (Fig. 1). Current hypothesis sug-
gests that these tripartite pumps export substrates from the 
outer leaflet of the inner membrane (IM) and the periplasm 
across the OM into the external medium [62, 65, 72-77]. The 
efficiency of RND pumps is synergistically associated with 
the presence of single-components pumps located in the IM 
and able to flush out substrates from the cytoplasm [78, 79]. 
 
 
Fig. (1). Schematic drawing of the assembled AcrAB-TolC tripar-
tite multidrug efflux system from Gram-negative E. coli. AcrB 
(RND component, in blue color) resides in the IM and is responsi-
ble for substrate recognition/selection and energy transduction. 
Drug uptake is coupled to a flux of protons from the periplasm to 
the cytoplasm. TolC (OMF component, yellow) forms a pore in the 
OM which is extended by a long periplasmic conduit. AcrA (MFP 
component, red) mediates contact between AcrB and TolC. The 
presence of all three components is essential for the MDR pheno-
type. Taken from Ref. [204]. 
 
Fig. 1 shows a model of the tripartite pump AcrB-AcrA-
TolC, the major, constitutively expressed efflux pump in E. 
coli [80, 81]. Homologous pumps are present in all Gram-
negative bacteria (e.g. MexB-MexA-OprM in P. aeruginosa 
[82-84]). The IM component AcrB is a proton/drug homo-
trimeric antiporter key to both energy transduction and sub-
strate specificity of the entire three component setup [80, 85-
87]. Homologs of AcrB are widespread not only in Gram-
negative bacteria but also in Gram-positive ones, as well as 
in eukaryotic cells [88-90]. TolC is a homotrimeric outer 
membrane factor (OMF), a channel that is involved in the 
efflux of antibiotics and proteins [72, 91-98]. AcrA is a 
membrane fusion protein (MFP), an adaptor protein that is 
proposed to stabilize the assembly of the pump and to con-
tribute to the transfer of efflux-coupled conformational tran-
sitions from AcrB to TolC [80, 99-101]. AcrA is required for 
the functioning of AcrB in intact cells [81]. The X-ray struc-
tures of all the components have been resolved by X-ray 
crystallography, but the structure and the stoichiometry of 
the functional assembly are still under debate [75, 76, 91, 94, 
102-104].  
Several excellent reviews have been published in the re-
cent years addressing the link between MDR and RND ef-
flux pumps, either from a broad perspective [34, 44, 47, 48, 
56, 58, 63-65, 100, 105-107] or focusing on particular sys-
tems [55, 62, 73, 91, 108-111] and methodologies [41, 77].  
In this review we focus on the secondary active antiporter 
AcrB of E. coli, which is responsible for the recognition and 
the initial extrusion of substrates (driven by proton motive 
force across the IM), and is by far the best-studied RND pro-
tein. The most striking characteristics of AcrB are its ex-
tremely wide substrate specificity and high constitutive ex-
pression levels under stress conditions [65]. The natural 
function of AcrAB-TolC is proposed to be removal of bile 
salts detergents and their derivatives, steroid hormones and 
host-defence molecules present in high concentrations within 
the natural habitat of E. coli [68, 87, 112]. However, this 
system extrudes several other neutral, zwitterionic, cationic 
and anionic compounds (Fig. 2) [48, 64], including basic 
dyes (acriflavine and ethidium), simple solvents (hexane, 
heptane, octane, nonane, cyclohexane), and moreover most 
of the known antibiotics (macrolides, fluoroquinolones, -
lactams, tetracyclines, chloramphenicol, rifampin, novobio-
cin, fusidic acid) [56, 113, 114]. The only common charac-
teristic of these substrates is a certain degree of hydrophobic-
ity/lipophilicity [115]. Indeed, a class of antibiotics that is 
not recognized by AcrB are the aminoglycosides such as 
kanamycin and streptomycin, which are more hydrophilic 
molecules. The fact that antibiotics are substrates of efflux 
pumps is actually not surprising, as these pumps are impli-
cated in the export of antibiotics by antibiotic-producing 
bacteria [116].  
In the following we analyze structural, computational, 
and biochemical studies performed over the last decades on 
AcrB and related proteins. Based on this analysis we outline 
a putative mechanism of substrate uptake, recognition and 
extrusion, and of AcrB inhibition. These mechanisms are 
compatible with the available data and should be applicable 
to homologous RND transporters. We start with the descrip-
tion of the structural features of AcrB and of the mechanism 
of substrate uptake and binding. Then we describe the cur-
rent view about the molecular mechanism of substrate extru-
sion by concerted conformational changes in the antiporter. 
Finally, we describe the ongoing strategies aimed at 
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Fig. (2). A selection of molecules interacting with the RND transporter AcrB. The substrate structures are displayed in panels containing anti-
biotics, dyes, solvents and detergents. Inhibitors and non-substrates are collected in the lower panels. 
 
inhibiting efflux by RND pumps, with a focus on inhibitors 
of AcrB. 
STRUCTURAL FEATURES OF THE ANTIPORTER 
ACRB AND CONNECTION TO SUBSTRATE UP-
TAKE AND AND RECOGNITION 
The gene encoding the 1049-aa long membrane-spanning 
drug/proton antiporter AcrB was identified in 1993 and some 
years later it was shown that the conversion of the electro-
chemical energy across the biological membrane into extru-
sion of substrates occurs in the transmembrane (TM) region, 
which facilitates H+ transport [66, 86, 87]. Two large perip-
lasmic loops connected to the TM domain are involved in 
substrate recognition. On the basis of periplasmic domain 
swapping experiments with AcrB and other RND transport-
ers [117, 118], these loops were proposed to contain multiple 
sites of interaction (each possibly with multi-drug binding 
features) for the various structurally diverse compounds. 
In 2002, the first three dimensional X-ray structure of 
AcrB became available [85]. The crystallographic data was 
derived from a crystal grown in a R32 space group and rep-
resented a symmetric AcrB homotrimer free of substrate. 
The shape of the protein resembles that of a jellyfish (Fig. 3). 
Viewed orthogonally to the membrane plane, each protomer 
elongates for ~120 Å, comprising a TM region of ~50 Å 
composed of 12 -helices (TM1 to TM12), and a periplas-
mic headpiece of about 70 Å. The latter is divided into a 
pore (porter) region, formed by four -strand – -helix – -
strand subdomains (designated PC1, PC2, PN1, PN2), and in 
an upper region, formed by two mixed -sheet subdomains 
(DN and DC) (Fig. 3a).  
The TM domain shows a pseudo-two-fold symmetry axis 
with the six N-terminal helices translationally symmetrical to 
the six C-terminal ones (Fig. 3c, 3d). Interesting exceptions 
are represented by helices TM2 and TM8, both extended out 
of the TM domain towards the periplasmic pore domain. In 
addition, TM8 shows a disordered loop structure at the perip-
lasmic side (residues 860-868) (Fig. 3d). Another interesting 
observation is the presence of a groove extending across the 
whole TM domain between helices 7 and 8, shallow at the 
cytoplasmic side of the membrane and deep at the periplas-
mic side due to the tilting of TM9 (Figs. 3a and 4a, 4f). This 
groove was proposed to be a possible recognition site for 
AcrB substrates [85]. The three TM domains (one for each 
protomer) form a large cavity of about ~30 Å in diameter, 
likely filled with phospholipids in vivo. 
The pore domain (Figs. 3a, 3b) comprises two interesting 
topological features at subdomains PN1 (a pore helix, N2) 
and PC1 (a short hairpin, C2’–C3’) (Figs. 3a, 3d). The 
three helices N2 delimit the central pore formed by the ar-
rangement of the three protomers and connecting the upper 
region (see below) down to the central cavity located at the 
bottom of the headpiece just above the membrane plane. 
Notably, a hairpin (hook-like bend in Ref. [85], switch-loop 
in Ref. [119] or G-loop in Ref. [120]) is present at the depth 
of the periplasmic cleft formed by subdomains PC1 and PC2 
in each protomer, which has been shown to be important for 
substrate adaptation [119, 121]. 
The relative arrangement of the AcrB monomers and the 
putative presence of phospholipids within the central hole 
delineated by the TM domains of each protomer result in the 
formation of 3 inter-monomer vestibules, each extending 
~15 Å above the membrane plane and connecting the central 
cavity of the protein with the periplasm. It was suggested 
that substrates immersed within the outer leaflet of the mem-
brane can enter this central cavity, which was also 
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Fig. (3). Structure and secondary structural elements of AcrB. A) Side view of the structure of the AcrB asymmetric homotrimer. The A 
monomer is shown in solid ribbons, with different colors highlighting the main domains and subdomains of the pump. The remaining mono-
mers are shown in transparent ribbons. B) Top view of the periplasmic domain of AcrB, showing the three monomers A (cyan), B (yellow) 
and C (red). The TM domain has been removed for clarity. C) Top view of the TM domain of AcrB (adapted from Ref. [131]). The color 
code is the same as in B, but the TM domains are divided in two regions to highlight the symmetry between the TM1-6 (darker colors) and 
TM7-12 moieties (lighter colors). Key helices contributing to the proton-relay network and to the transmission of allosteric conformational 
changes to/from the periplasmic domain are indicated by black labels in the A monomer, while gray labels indicate helices 1 of A and C 
monomers and 8 of monomer B. D) Subdomains and secondary structural elements within a monomer of AcrB (Adapted from Refs. [132] 
and [85]). 
 
considered as a possible recognition site for the uptake of 
substrates [66].  
A third domain is present above the pore domain, featur-
ing an internal funnel with a diameter of ~30 Å at the most 
distal side but closed at the bottom by the tight interaction of 
the three pore helices of the pore domain (Figs. 3a and 3d). 
The upper diameter matches that of the proximal entrance of 
the TolC protein [92], and thus that domain was tentatively 
called TolC docking domain. 
The first structures of AcrB in complex with ligands 
(rhodamine 6G, ciprofloxacin, dequalinium and ethidium), 
derived from diffraction data at resolutions of 3.5-3.8 Å, 
were released in 2003 [122]. The differences with respect to 
the previous structure (which was used for phasing in these 
experiments) were negligible, and the AcrB monomers, each 
with a ligand bound within the large central cavity approxi-
mately at the level of the outer leaflet of the IM, were ar-
ranged also in a symmetric configuration (Figs. 4a, 4g). Al-
though in these structures each ligand is coordinated by a 
slightly different subset of AcrB residues, the primary bind-
ing interactions were always hydrophobic in nature, and at 
least with rhodamine 6G, dequalinium and ethidium, mutual 
interactions among the three ligands were also evident [122]. 
These structures supported the hypothesis of substrate en-
try from the inter-monomer vestibules towards the central 
cavity [66, 85] and the hypothesis of the dual entrance model 
postulated by Nikaido et al. [115]. Site-directed mutagenesis 
seemed to confirm the role of the central cavity in substrate 
binding, as the F386A mutation nearly abolished the efflux 
activity [108], but it was recognized later that those results 
were likely flawed by the use of high-copy-number vectors 
[65]. In fact, binding of these substrates to AcrB appears to 
be quite peripheral and loose (only two residues were found 
within 4.5 Å of the ligand in all structures), and the authors 
had to include interactions with phospholipids in the defini-
tion of “binding sites” [65, 108, 122].  
Consistent with these interpretations are the 3.1-3.8 Å 
resolution structures of AcrB with bound ciprofloxacin, 
ethidium, rhodamine 6G, nafcillin and Phe-Arg--
naphthylamide (PAN or MC-207,110, Fig 2) solved by Yu 
et al. in 2005 [123] using a N109A variant of AcrB. The 
symmetric structure of the N109A variant was overall very 
similar to that of wt AcrB, but the binding positions of 
ligands within the central cavity were somewhat different 
with respect to those reported earlier [122], yet still periph-
eral. Moreover, in each structure there was a second ligand 
reported to be bound to the PC1/PC2 periplasmic cleft. The 
ligands appear to have more tight interactions with side 
chains of AcrB in this region compared to the reported sub-
strate binding in the central cavity. In these structures bind-
ing of ligands involves primarily residues F664, F666, E673, 
R717 (Fig. 4e). Subsequent alanine substitution of these 
residues decreased the MIC of most of the tested agents both 
in the N109A variant and wt AcrB background (in particular 
true for E673A, although to a lesser extent in the wt) [122]. 
Interestingly, residues F664, F666 and E673 were later con-
firmed to be involved in the extrusion pathway of AcrB sub-
strates [124]. 
After 2005, several other structures of AcrB featuring a 
symmetric arrangement of the three monomers were pub-
lished at resolutions between 3.1 and 3.9 Å, both free of sub-
strates [125] and in complex with ampicillin [126], bile acid 
[127] and linezolid [128].  
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Fig. (4). Structures of AcrB-substrate complexes. a) Side view of AcrB monomers A (yellow) and B (cyan) bound to substrates of the pump 
as found in X-ray crystal structures published up to date. The substrates are minocycline, doxorubicin, erythromycin, rifampicin, linezolid, 
ethidium, ciprofloxacin, rhodamine 6G, dequalinium, nafcillin, ampicillin, bile acid, PAN, D13-9001. Substrates co-crystallized within 
AcrB asymmetric and symmetric structures are shown with thick and thin sticks respectively. Binding positions of additional ligands as pre-
dicted by docking and/or MD simulations [120, 135] for additional substrates, are not shown for clarity. Labels indicate the deep (DP) and 
access (AP) pockets identified only in the asymmetric X-ray structures. The external PC1/PC2 subdomain cleft (CL), central cavity (CC), and 
vestibule (VB) are also indicated. Ligands are represented by colored sticks, with dodecyl--D-maltoside is shown in grey sticks in the VB 
and CC, and dodecyl--D-maltoside shown in white sticks in the DP of monomer B (below the inhibitor D13-9001 in black sticks). b-g): 
Close-up view on the DP of monomer B (b), AP of monomers A (c) and B (d), CL (e) and VB (f) between monomers A and B, and CC (g) 
displaying residues involved in liganding substrates. Residues are shown with sticks not including hydrogens. Hydrophobic residues are 
shown translucent, while the other residues (polar and charged ones) are rendered in pencil. Residues putatively involved in substrate trans-
port as by biochemical cross-link experiments [124, 144], are shown in thicker sticks and are indicated by their residue number. In (d) and (f) 
also the dodecyl--D-maltoside molecules are shown with sticks colored according to the atom type. 
In Ref. [125] a possible role of conserved residues F4 and 
F5 in the recognition of substrates from the cytoplasm was 
proposed. The authors obtained a symmetric trimeric model 
with a resolved N-terminal stretch, which appears to narrow 
the cytosolic opening of the central cavity. Interestingly, 
alanine-substitution of F4 and F5 in MexB resulted in the 
change of susceptibility of cells towards those compounds 
that have their inhibitory effect on targets in the cytosol 
[129]. Whether this observation can be transferred to other 
RND drug efflux pumps remains to be investigated. 
In Ref. [126] two molecules of ampicillin per monomer 
were bound to the central cavity of AcrB. Furthermore, the 
transmembrane protein YajC was co-crystallized bound to 
the external side of the TM domain of AcrB. This interaction 
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appeared to cause a slight conformational change on AcrB 
with respect to previous symmetric structures, which was 
progressively more prominent from the TM to the TolC 
docking domain, and suggested to be casual for opening the 
proximal gate of TolC. However, the presence of YajC did 
not significantly influence the efflux of -lactams tested 
[126]. 
The latest symmetric structures of AcrB were published 
in 2008 [127] and 2013 [128], showing the transporter in 
complex with taurocholic acid bound to the cleft (Fig. 4e) or 
with linezolid bound to the central cavity (Fig. 4a, 4g), re-
spectively. 
The comparison among the above structures reveals a 
certain degree of flexibility in the periplasmic domain of 
AcrB. With the purpose to obtain the structure of intermedi-
ate conformations linked to alterations in protonation of the 
key residues in the TM domain (see next section), Nikaido 
and co-workers crystallized in 2006 a series of four AcrB 
variants with alanine-substitutions of D407, D408, K940 and 
T978, residues putatively involved in proton translocation 
across the IM [130]. Interestingly, the network of interac-
tions present in wt AcrB was disrupted in all the variants. 
Indeed, K940 flipped away from residues 407 and 408 in the 
D407A mutant, although this interpretation could be partly 
flawed by the lack of electron density for the K940 side-
chain. The putative disruption of the salt-bridges network 
induced shortening of several helices in the TM domain, in 
addition to a significant extension of TM8 towards the perip-
lasmic PC2 subdomain coupled to a slight movement of this 
subdomain towards subdomain PC1. However, apart from 
this conformational change, no propagation of structural al-
terations from the TM to the periplasmic domain was re-
ported in that study. Moreover, structures were based on 
diffraction data of moderate resolution (3.4-3.6 Å), making 
interpretation difficult. 
With the publication of three reports in 2006 and 2007 of 
three asymmetric structures of AcrB [131-133], based on 
diffraction data of higher resolution than before (2.5-3.3 Å) 
and obtained from crystals grown in different space groups 
(C2, P1 and P212121), a clearer picture arose concerning sub-
strate binding and mechanism of drug transport by AcrB. In 
the asymmetric structures, each monomer of the trimer 
adopts a different conformation featuring channels inside the 
periplasmic domain either open towards the periplasmic 
space or towards the funnel in the TolC docking domain 
(Fig. 5).  
One of the monomers, called A [133] or Loose (L) [132] 
or Access [131], closely resembled the structure found in the 
symmetric arrangement of AcrB. It features channels con-
necting a cavity located near to the G-loop (Fig. 3a) to the 
PC1/PC2 cleft, to the side wall of the vestibule formed by 
residues S836, E842, L868 and Q872, and to a very small 
gate leading to the central cavity (Fig. 5a, and see Table 1 
for definition of residues lining the key regions of AcrB).  
The B or Tight (T) or Binding monomer had an overall 
conformation similar to A, but major differences stemmed 
from a significant shift of the PN2 subdomain towards the 
PN1/PC1 subdomains of monomer A, apparently creating a 
phenylalanine-rich deep (or distal) binding pocket (hereafter 
DP) between the -sheets of subdomains PC1 and PN2 (Fig. 
4). This pocket readily accommodates substrates of the 
pump, as structures by Murakami et al. displayed the two 
substrates minocycline and doxorubicin bound to it [131]. As 
with the A monomer, also the B monomer features a channel 
connecting the DP to the PC1/PC2 cleft entrance and to the 
TM7-9 groove at the level of the membrane/periplasm inter-
face (Fig. 5b). 
Interestingly, the conformation of the DP (as well as the 
overall structure of the trimer) in the asymmetric structures 
crystallized without added substrates of the pump [132, 133] 
are very similar to the one with bound substrates. It was sug-
gested that bound substrate (in these cases the solubilizing 
detegernt dodecyl- -D-maltoside) was present in the DP but 
not visible due to the lack of binding restraints and/or to in-
sufficient resolution. Consistent with this hypothesis are the 
results of recent all-atom MD simulations of substrate-free 
AcrB in a 150 mM NaCl solution (without detergent but with 
the TM domain embedded in a palmitoyloleoyl-
phosphatidylethanol-amine – POPE – bilayer), showing the 
collapse of the hydrophobic DP of monomer B after a short 
simulation time [134]. 
An analysis of the binding positions of minocycline and 
doxorubicin reveals a set of different residues liganding the 
two substrates within this pocket (however, F178 and F615 
are common), a finding that is compatible with the wide sub-
strate-recognition spectrum of AcrB. The promiscuity of the 
DP in accommodating different substrates was further sub-
stantiated by two recent computational studies addressing the 
binding of several compounds to this pocket in the B mono-
mer [120, 135]. In Ref. [135] about 30 compounds were 
docked to the DP of the B monomer. Many of these com-
pounds were predicted to bind to a narrow groove at one end 
of the pocket (groove binders), whereas some prefer to bind 
to a wide cave at the other end of the pocket (cave binders), 
and a third group of compounds were found docked in be-
tween the groove and the cave (mixed binders). The distinc-
tion between groove and cave binders was fairly consistent 
with labeling and competition experiments (although the 
number of compounds tested was limited), and with the 
presence of two “multifunctional-sites” (able to bind aro-
matic, hydrophobic, polar groups) on the two ends of the DP 
[136]. In a subsequent study with docking and MD simula-
tions complemented by free energy and surface matching 
calculations [120], the distinction between groove, cave and 
mixed binders became somewhat blurred, although the bind-
ing positions of substrates confirmed the presence of a very 
wide and multifunctional pocket of exceptional promiscuity 
(Figs. 4a, 4b and 6a). Residues F136, Q176, F178, I277, 
V612, F615, R620 and F628 contributed most to the stabili-
zation of substrates (Fig. 6b). Interestingly, all of these resi-
dues but V612 were found to be part of the substrate path 
through the AcrB pore domain as was shown in intact-cell 
experiments [124]. Furthermore, a wide spectrum of interac-
tion types were identified in the DP (15 hydrophobic resi-
dues and 11 polar or charged amino acid residues were found 
to contribute to the binding, Fig. 6b), consistently with the 
multidrug recognition capacity of AcrB.  
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Fig. (5). Tunnels and substrate entry gates present in the periplasmic pore domain of AcrB. Tunnels are shown in green transparent surfaces 
and the center of mass of the main cavity is also shown as darker transparent surface, indicated by a black arrow and centered in the AP, DP 
and exit gate in A, B, and C respectively. Protein is shown in gray ribbons, with the G-loop in yellow and the PC2 and PN1 subdomains ren-
dered transparent for clarity in a). Solid colored spheres represent the residues found to be involved in cross-linking the substrate upon Cys-
modification [124, 144]: the exit gate to the TolC docking domain (residues Q124 and Y758; ice blue), the extended pocket (Q89, S134, 
F136, Q176, F178, N274, D276, I277, G290, Y327, M573, R620, F628; red), the bottom of the Cleft (D566, T676, E673; purple), the Cleft 
(F664, F666, L668, R717, L828; orange), Vestibule (S836, E842, L868, Q872; pink) and Central cavity (G97; azur). The latter three en-
trances are indicated by arrows and bolded tags. The tunnels indicated were derived from calculations using CAVER 3.0 [205]. The structures 
shown are based on pdb entry 2J8S [133], subsequently relaxed through MD simulations in presence of water and a POPE bilayer (A. V. 
Vargiu, unpublished). a) Monomer A; b) Monomer B; and c) Monomer C. 
 
Table 1.  Residues Identifying Key Regions of AcrB Involved in Substrate Uptake and Extrusion (from Refs. [119, 121, 124, 131, 
144]), Along with their Hydrophobicity/Hydrophilicity Profiles. Residues Shared by the Cleft and the Access Pockets are 
Italicized, while those Shared Between the Access and the Deep Pockets are Underlined. Residues Identified as Part of the 
Extrusion Path of AcrB Substrates are Bolded. 





Distal/Deep Pocket  
S46 Q89 S128 E130 S134 F136 Q176 L177 
F178 S180 E273 N274 D276 I277 G290 
Y327 M573 F610 V612 F615 F617 R620 
F628 
52 30 4 13 
Access/Proximal Pocket 
S79 T91 S134 S135 K292 M573 M575 
Q577 F617 T624 M662 F664 F666 N667 
L668 L674 T676 D681 R717 N719 E826 
41 41 9 9 
Cleft 
D566 F664 F666 L668 E673 T676 R717 
L828 
50 12.5 12.5 25 
Vestibule S836 E842 L868 Q872 25 50 - 25 
Central Cavity G97 - 100 - - 
Gate Q124 Q125 Y758 33.3 66.6 - - 
 
The third monomer, C or Open (O) or Extrusion (E), fea-
tured the largest structural difference compared to the struc-
ture of the monomers as found in the symmetric state. While 
the details of these conformational changes will be discussed 
in the next section, we anticipate that this monomer features 
a channel leading from the (collapsed) DP to the central fun-
nel, as well as significant rearrangements in the TM domain. 
It is also worth noticing that the N-terminal stretches fold as 
helices in the asymmetric structures, significantly opening 
the bottom of the central cavity with respect to the structure 
reported in Ref. [125]. 
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Fig. (6). Residues in the AcrB periplasmic pore domain involved in substrate interaction based on computational studies [120]. a) Residues 
are shown in stick representation. The thickness of each residue is proportional to its frequency of binding contact to the tested sub-
strates (minocycline, taurocholic acid, erythromycin, nitrocefin, chloramphenicol, ethidium, oxacillin, ciprofloxacin, NMP, PAN). The DP 
and AP, the PC1/PC2 subdomain entrance cleft, and the DP/AP interface are shown in transparent red, green, orange, and yellow surfaces. 
The G-loop is shown in yellow. Bold labels refer to residues involved in binding of more than three different substrates (inhibitors or not). 
The thick purple line roughly highlights the shared region of the binding site drawn according to this analysis. b) Histogram showing, for 
each residue (on the x axis), the number of substrates for which the contribution to the binding free energy by that residue is larger than 
kT0.6 kcal/mol. Hydrophobic, polar and charged residues are identified by black, green, and red bars respectively. The sum over all frequen-
cies is reported above each group of residues. Adapted from Ref. [120]. 
 
In addition to the DP present in the B monomer, a more 
proximal or access pocket (hereafter AP, Figs. 4a, 4c) was 
recently identified in the A monomer by two independent 
studies, publishing the structure of AcrB in complex with 
erythromycin and rifampicin [121], and a doxorubicin dimer 
[119]. The newly identified AP was located deeper into the 
PC1/PC2 cleft compared to the more peripheral binding site 
found in Ref. [123], and is separated from the DP by the G-
loop [119-121] (Fig. 4a). The different binding poses found 
in the structures of AcrB co-crystallized with erythromycin, 
rifampicin and doxorubicin within the AP [119, 121] reveal 
its promiscous binding properties, shared with the DP and 
consistent with the broad specificity of AcrB. Importantly, 
ternary complexes with one substrate bound to the DP in the 
B monomer and a second to the AP of the A monomer 
within the same AcrB trimer were reported in Refs. [119, 
121]. This finding is notable, as it has been postulated earlier 
on [62, 132] that allosteric bi-site activation of the AcrAB-
TolC efflux pump might be essential for antiporter function-
ing (we will return on this aspect in the next section).  
The large size of the compounds (notice that doxorubicin 
bind as a dimer) bound to the AP led to the hypothesis that 
AcrB recognizes high molecular-mass (HMM) substrates via 
this binding site, while low molecular-mass (LMM) sub-
strates are not recognized by the AP but bind directly to the 
DP [121]. The higher affinity of erythromycin to the access 
than to the distal pocket was confirmed by free energy and 
hydrophobic surface matching calculations performed on 
trajectories of AcrB-substrate complexes [120]. On the ex-
perimental side, fluorescence-quenching experiments on 
AcrB variants bearing bulky side chain substitutions in the 
AP showed severe effects on doxorubicin efflux [121]. In 
addition, it was shown that the inhibition of doxorubicin ef-
flux by erythromycin, occurring with wt AcrB, disappeared 
when residues involved in erythromycin binding were substi-
tuted with bulky aminoacids. In contrast, the F610A muta-
tion in the DP reduced both doxorubicin and erythromycin 
resistance, and the efflux of the former substrate was signifi-
cantly abrogated, as confirmed by two additional studies 
[137, 138].  
The position and the flexibility of the G-loop seem to be 
important for the efflux of HMM substrates, as confirmed by 
several findings: a) A G616N AcrB variant deficient in mac-
rolide transport [139] features a conformation of the loop in 
the A monomer resembling that of wt MexB (bearing N616 
and unable to expel macrolides) in the same monomer [140] 
and to that of the B monomer in wt AcrB [119]; b) a compa-
rable loop conformation was found in the X-ray structure of 
the G616P/G619P AcrB variant [121], which was designed 
to hinder conformational changes of the G-loop. This finding 
is consistent with a recent computational study highlighting 
the different flexibilities of wt and G616P/G619P loops 
[141]; c) The growth of mutants G616P/G619P and 
G614P/G621P was abrogated under sub-inhibitory concen-
trations of doxorubicin or erythromycin, and this was cou-
pled to impaired efflux of these substrates [121].  
In summary, the broad specificity of AcrB is likely due 
also to the presence of two large multi-functional binding 
pockets separated by a flexible loop acting as a gate between 
them. 
EXTRUSION OF SUBSTRATES BY ACRB: 
CHANGES IN PERIPLASMIC DOMAIN AND COU-
PLING TO PROTON MOTIVE FORCE BY PROTON 
UPTAKE AND RELEASE IN THE TM DOMAIN 
A mechanism for the extrusion of antibiotics by RND ef-
flux pumps was firstly hypothesized in 1994, following the 
observation that good substrates of MexB were unable to 
penetrate the cytoplasm [55]. Nikaido and co-workers pro-
posed a dual entrance model in which substrates are taken up 
from the periplasm (or the periplasm/IM interface) and from 
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cytosol (or the cytosol/IM interface (Fig. 7a). This model 
was supported by several additional pieces of evidence. For 
example, Zgurskaya and Nikaido [86] showed that purified 
and reconstituted AcrB catalyzed the export of fluorescence-
labeled phospholipids from within the bilayer. Additionally, 
according to Nikaido et al. [115], among -lactams only 
those with lipophilic side chains were efficiently pumped out 
by AcrB. On the other hand, aminoglycosides, which are 
more hydrophilic molecules compared to the substrates of 
AcrB, are expelled by RND transporters MexY [142] and 
AcrD [143]. Thus, another model might be needed to de-
scribe the uptake of these compounds by RND transporters. 
It is worth noticing that the current hypothesis about sub-
strates extrusion partly overlaps with the dual entrance 
model, as it assumes that compounds enter the transporter 
from the outer leaflet of the IM (through the TM7-9 groove) 
or directly from the periplasmic cleft [119, 121, 124, 144]. 
As pointed out in the previous section, a breakthrough in 
the understanding of mechanistic aspects of efflux by RND 
transporters arose in 2006/2007 with the publication of the 
asymmetric structures of AcrB [131-133]. It is believed that 
such structures represents the most populated conformation 
in the presence of substrates [62, 110, 119, 121, 145, 146] or 
inhibitors [18, 120], while the former symmetric structure 
might represent the “resting state” of the pump, preferred in 
the absence of substrates tightly bound to the protein [62, 65, 
110, 134, 145]. 
On the basis of the X-ray structures, a “functional rota-
tion” mechanism (Figs. 7b and 8) was postulated to explain 
drug export by AcrB, involving a concerted - but not neces-
sarily synchronous [62, 111, 119] - cycling of the monomers 
through any of the asymmetric states A, B, C, and back to A. 
During a complete cycle ABCBCACABABC occlu-
sions and constrictions inside the pore domain propagate 
from external gates towards the central funnel (Fig. 5), driv-
ing the unidirectional transport of substrate (hence the defini-
tion of “peristaltic pump mechanism” [132]). Thus, guided 
translocation appears to be the mechanism of substrate trans-
port within the AcrB monomers. This is compatible with the 
multi-site properties of the affinity sites discovered so far 
[119-121, 131], as also confirmed by a recent computational 
investigation of multi-functional sites in the asymmetric 
structure of the pump [136]. In Ref. [136] it was shown that 
binding sites are different in each of the AcrB monomers, 
implying that a drug avoids being trapped in one location 
through site-specific interactions. In addition, the authors 
shown that a complicated free-energy balance originating 
from weakly polar and weakly hydrophobic surroundings 
maintains substrates in the pockets, a finding confirmed for 
the DP by a recent computational study of the interaction 
between AcrB and series of its substrates [120]. 
In the A conformation, substrates are recruited from the 
periplasmic space (PC1/PC2 cleft) and/or the membrane 
(vestibule or central cavity) and bind a wide region that in-
cludes the AP. More precisely, substrates partitioned in the 
outer leaflet of the IM can bind to the TM7-9 groove or to 
the entrance lined by G97 in the central cavity of the A 
and/or B monomers [62, 65, 73, 144]. More hydrophilic sub-
strates located in the periplasm might bind to the PC1/PC2 
cleft of monomers A and B [119, 121, 123, 124]. 
A concerted and consecutive drug uptake via the outer 
leaflet gates and subsequent transport to the cleft might be 
envisioned [119], but a recent computational study shows 
that periplasmic and TM7-9 gates appear to be quite specific 
for less and more hydrophobic/lipophilic compounds [147], 
respectively. In this respect, it is worth recalling that n-
dodecyl--D-maltoside was found to bind relatively tightly 
both to the TM7-9 groove in the A monomer and to the 
PC1/PC2 cleft in the B monomer in the highest-resolution X-
ray structures reported so far [119, 133]. 
Along the A to B transition substrates move from the AP 
toward the DP, the second site being more hydrophobic than 
the former, consistently with the physico-chemical properties 
of substrates of the pump, which share a certain hydropho-
bicity [119, 121] (Table 1). The G-loop was suggested to act 
as a gate between these two pockets, and indeed its flexibil-
ity was shown to be crucial for the functioning of the pump 
[119, 121, 141]. Inhibitors were found to straddle this loop, 
which lead to the hypothesis of an action by hindering con-
formational changes of the transporter and/or blocking the 
substrate pathway by binding to that region [120]. No major 
conformational changes in AcrB are apparent along the 
AB step of the cycle, except for a partial coil-to-helix tran-
sition of TM8 and moreover a shift and a rotation of the PN2 
subdomain, likely stabilized by the binding of substrates in 
the DP [131-133] (Figs. 8a-c). 
Upon transition from the B to the C conformation, sub-
strates are squeezed out from the binding pocket and they 
exit AcrB via its central funnel toward the TolC tunnel [131-
133]. The squeezing traces back to the complete rewinding 
and to the kinking of TM8, which assumes a full helical 
structure compared to the coil and helix/coil conformations 
in A and B monomers. These conformational changes of 
TM8 are most likely due to the different protonation states of 
TM domain residues D407 and D408 in the respective 
monomers (Figs. 8d and 9). The recovery of helical confor-
mation by TM8 coincides with a significant shift of the PC2 
subdomain towards PC1 and towards the membrane plane. 
As a consequence, the PC1/PC2 cleft closes towards the pe-
riplasm, thus blocking the entrance and the exit of substrates 
along this path (Figs. 8a, 8b, 8d). This movement is also due 
to the constraints imposed on PC2 by subdomain PN2, which 
moves after binding of substrates to the DP of monomer B 
(Figs. 8a, 8d). The shift of PC2 coincides with a tilting of 
subdomain PN1 (containing the pore helix N2) by ~12° 
towards subdomains PN1 and PN2 of the adjacent B mono-
mer and away from PN2. Consequently the movement of 
subdomain PN1 also opens a channel forming a substrate 
exit gate from the collapsed DP towards the central funnel 
lined by residues Q124, Q125 and Y758 and the OM channel 
TolC (Fig. 8d). Interestingly, this mechanism highlights the 
role of the flexibility in the region of pore helices N2, and 
help explaining the outcomes of experiments on proteins 
bearing mutations thereon [148]. 
The displacement of the substrate out of the DP and to-
wards the Gate to the central funnel (Figs. 5b, 5c) along 
BC has been supported by two computational studies [145, 
149]. In Ref. [145] a coarse grain model of the AcrB pore 
domain (Fig. 3a) and of the substrate was employed to di-
rectly observe extrusion of the latter during the BC con-
formational transition. In Ref. [149] targeted MD simula-
tions were performed on a full all-atoms model of AcrB in 
10    Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 24 Ruggerone et al. 
 
Fig. (7). Functional rotation mechanism of substrate extrusion by AcrB. a) Early schematic view of the tripartite AcrAB-TolC complex [65]. 
Note that amphiphilic drugs (empty and solid rectangles represent hydrophobic and hydrophilic parts of the molecule) are hypothesized to be 
captured at the interface between the IM and the periplasm or the cytoplasm. For the latter process, two possible pathways are envisaged 
(dashed arrows): Either the substrate is flipped over to the outer leaflet of the IM first and then follows the anticipated capture from the perip-
lasmic side or it follows a different capture pathway from the cytosol; b) Schematic representation of the AcrB alternating site functional 
rotation transport mechanism. The conformational states A, B and C are colored blue, yellow and red, respectively. Upper panel: Side-view 
schematic representation of two of the three monomers of the AcrB trimer. AcrA and TolC are indicated in light green and light purple colors, 
respectively. Lower panel: The lateral grooves in the A (blue) and B (yellow) monomers indicate the substrate binding sites. The different 
geometric forms reflect low (triangle), high (rectangle), or no (circle) binding affinity for the transported substrates. In the first state of the 
cycle, a monomer binds a substrate (acridine) at the access site (AP in the A monomer), subsequently transports the substrate from AP to the 
DP (upon conversion to B monomer) and finally releases the substrate in the funnel toward TolC (C monomer). AcrA is postulated to partici-
pate in the transduction of the conformational changes from AcrB to TolC, which results in the opening of the TolC channel and the facilita-
tion of drug extrusion to the outside of the cell. Adapted from Ref. [132]; c) Schematic representation of the AcrB alternating site functional 
rotation transport mechanism extended by postulated intermediate steps. The lateral grooves in A and B monomers indicate the substrate 
binding sites. The different geometric forms reflect low (triangle), high (rectangle), or no (circle) binding affinity for the transported sub-
strates. State BBB is postulated to occur at high substrate concentration, while AAA and AAB are postulated to occur in the absence or at low 
substrate concentrations. Adapted from Ref. [62]. 
 
complex with doxorubicin bound to the DP, such as to 
mimic the BC step of the functional rotation. Although 
full extrusion was expectedly not seen within the relatively 
short times affordable by such simulations, a significant dis-
placement of almost 10 Å was observed towards the exit 
gate. Interestingly, doxorubicin remained stuck in front of 
the exit gate during a series of targeted MD performed to 
mimic five complete cycles of the functional rotation (Var-
giu et al., unpublished data). Despite the limitations intrinsic 
to the methodology and the lack of AcrB partners in these 
studies, this finding is interesting as it might be indicating 
additional factors necessary for complete extrusion like e.g. 
the presence of more than one substrate inside the tunnel 
system as suggested recently (see Fig. 15 in Ref. [111]). In 
Ref. [149] it was also shown that detachment of the antibi-
otic from the binding site occurred with a zipper-like squeez-
ing of the pocket. Moreover, the concerted opening of the 
channel between the doxorubicin pocket and the Gate was 
shown to be necessary in order to displace the ligand.  
More in general, the importance of the flexibility of the 
AcrB trimer has been emphasized in a recent computational 
study of the transporter [134], showing clear opening and 
closing motions of the AP in A and B monomers, and of the 
exit gate in the C monomer. It appeared therefore from this 
study that each of the known three reaction cycle intermedi-
ates, as deduced from crystallographic studies, can adopt 
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Fig. (8). Conformational differences between the three AcrB monomers in the asymmetric structure (PDB code: 4DX5 [119]). a) Top view 
comparison between the asymmetric and the symmetric pore domains of AcrB. The symmetric structure is shown in transparent silver, while 
the asymmetric structure is superimposed in solid colors (monomers A, B and C are colored cyan, yellow and red respectively). Subdomains 
PN1, PN2, PC1 and PC2 of the pore region are labeled in the A monomer. Also the cleft of the A monomer and the vestibule between A and 
C are indicated. Major structural differences between the asymmetric and symmetric pore domain structure are shown with blue arrows. The 
size of the arrows is proportional to the RMSD calculated for the superimposed structures; b) Superimposition of the asymmetric and the 
symmetric TM domains of AcrB. Helices lining up this domain are labeled in the A monomer; c) Relevant conformational changes along the 
AB step of the functional rotation. No significant changes are seen in the TM domain (first panel), where the tight salt bridge between 
K940 and D407/408 is maintained. However, a partial winding of the TM helix 8 is clearly seen in the second panel, which leads to the open-
ing of the vestibule entrance of substrates (residues lining the vestibule and the bottom of the cleft are shown with pink and purple spheres, 
respectively). The third panel shows how substrate binding to the distal pocket (red spheres from the pocket belonging to PN1 or PN2 are 
shown) relocates the PN2 subdomain from PN1, which leads to further opening of the external cleft (orange spheres indicate residues lining 
that region); d) The salt-bridge between K940 and D407/D408 in the TM region are disrupted in monomer C (first panel), and this is associ-
ated to a further coil-to-helix transition of the TM helix 8 (second panel), which leads in turn to the closure of the vestibule and to a signifi-
cant rototranslation of the PC2 domain. This structural change “drags” the upper part of the PN1 subdomain away from PN2, leading to the 
opening of the exit gate towards the funnel and TolC and simultaneous closure of the DBP, due to the release of the substrate (third panel). 
The movement of the PC2 domain induces also the closure of the external cleft in addition to the vestibule (fourth panel); e) The salt bridge 
between K940 and D407/D408 in the TM region are reestablished in the A monomer (first panel), and TM helix 8 undergoes a backward 
helix-to-coil transition which partially opens the vestibule and causes a rotation and a shift of PC2 subdomain (second panel). This movement 
induces reorientation of the PN2 subdomain so that the N2’ helix (PN1 subdomain) closes the exit gate towards the funnel in the TolC dock-
ing domain (third panel). The movement of subdomain PC2 also reopens the external cleft between the PC1 and PC2 subdomains (fourth 
panel).  
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different conformations maybe indicating intermediate con-
formations between the three known states A, B and C. 
The authors of Ref. [134] speculate furthermore that AcrA 
could enhance the activity of the pump by stabilizing sub-
strate-accessible conformations, for instance by stabilizing 
PC1 and PC2 subdomain orientations. The importance of 
conformational coupling among the three monomers has 
been further assessed by an evaluation of the collective mo-
tions in AcrB [150]. However, as the authors pointed out, the 
collective motions represent the intrinsic conformational 
flexibilities that encode the allosteric couplings of the protein 
assembly. Their methodology indeed cannot elucidate the 
local conformational motions due to external factors such as 
substrate and protein partner binding or protona-
tion/deprotonation events). 
In addition to completely asymmetric conformations, the 
presence of intermediate states bearing more than one 
monomer in the A or B conformation, such as BBC or BBB, 
has been described by several authors [62, 111, 119], and 
supported by experiments [133, 146, 151] and computer 
simulations [145]. This might lead to a more complex 
mechanism for the extrusion of substrates, perhaps involving 
bi-site activation (Fig. 7c). For instance, the interaction of a 
substrate with the A monomer in the presence of a second 
substrate in the B monomer could be the prerequisite for the 
conformational change of the latter into the C state, associ-
ated with release of the substrate in the TolC docking do-
main funnel. Consistent with this more complex view are the 
recently observed strong cooperative kinetics of the extru-
sion of -lactam antibiotics by the AcrAB-TolC system [152, 
153], as well as the stimulation of cephalosphorin efflux by 
some AcrB substrates [154]. Moreover, the recent X-ray 
structures (discussed in the previous section) featuring si-
multaneous binding of substrates to the A and B monomers 
also support the possibility of cooperative mechanisms [119, 
121]. The interdependence of monomers has been confirmed 
by cross-linking experiments [151, 155] and by the use of an 
AcrB trimer with covalently linked monomers [156]. 
Moreover, the PN1 domain has been indicated as the “ratchet 
pin” for the transmission of these conformational changes 
[132]. 
As briefly mentioned in the description of the structural 
changes accompanying the B to C transition, the electro-
chemical proton gradient across the IM is most likely the 
driving force for the aforementioned conformational changes 
leading to uptake and extrusion of substrates in the periplas-
mic domain of AcrB. The role of the proton-motive force on 
the drug efflux activity has been shown via the effect of un-
couplers and ionophores in intact cells [87] and also with 
AcrA/AcrB reconstituted in liposomes using artificial proton 
motive force [86]. 
The flux of protons from the periplasm to the cytoplasm 
most likely involves rearrangements in the TM helices [130-
133, 157]. Protonation and deprotonation events, involving 
D407 and D408 primarily but also K940 and R971, induce 
conformational changes propagating towards the periplasmic 
domain (Figs. 8d and 9). It is believed that the B to C transi-
tion is the energy-demanding step of the cycle, with 2 pro-
tons being necessary to complete one cycle from A to B to C 
and back to A per monomer and per substrate transported 
(Fig. 9) [62, 65, 73, 110, 119, 133]. Once a substrate is 
bound to the DP in the B monomer, a conformational change 
propagates from PN2 to the TM domain, opening the path 
towards D407 and D408 for protons. Recent MD simulations 
by Fischer and Kandt [158] confirmed the existence of up to 
three connections to bulk water in the periplasm and one to 
bulk water in the cytoplasm in monomers A and B, while no 
connection was found in monomer C. Moreover, a signifi-
cantly larger and persistent hydration of the region contain-
ing the residues of the proton-relay pathway is seen in 
monomer B. Protonation of gating residues D407 and/or 
D408 was suggested to be the key step of the reaction [130-
133, 159]. In particular, D408 was shown to specifically re-
act with dicyclohexylcarbodiimide (DCCD) in a pH-
dependent manner [160]. The apparent pKa of 7.4 at D408 
would enable binding and release of protons under physio-
logical conditions. In contrast to other secondary transport-
ers, D408 was not protected by substrates against modifica-
tion, which supports the notion of spatially separated sub-
strate and proton transport pathways. In Ref. [158] the pro-
ton uptake event was also suggested to occur in the A or B 
state, or during a previously unknown intermediate in be-
tween B and C where cytoplasmic water access is still possi-
ble.  
This flux of protons across the membrane induces a con-
formational change in the TM8 that propagates to the pore 
domain, inducing the BC transition which lowers the af-
finity of the substrate to the DP and opens the Gate to the 
central funnel. The proton release event was suggested in 
Refs. [62, 158] to involve R971 in the C intermediate.  
SUMMARY OF SUBSTRATE UPTAKE AND EXTRU-
SION BY ACRB: LMM VS HMM COMPOUNDS 
Summarizing the data reported so far, two slightly differ-
ent mechanisms of extrusion by AcrB can be envisaged for 
LMM and HMM substrates. Concerning HMM substrates, 
after entry AcrB from the PC1/PC2 cleft or the vestibule, 
they bind to the AP in the A monomer and are then translo-
cated into the DP upon the A to B transition by a peristaltic 
mechanism involving subdomain movements that include a 
shift of the G-loop. These data clearly points to the impor-
tance of conformational changes of the G-loop coupled to 
translocation HMM substrates from the access to the distal 
pocket.  
On the contrary, LMM drugs could also travel through 
the AP until they reach the DP of the B monomer. This is 
consistent with recent coarse-grained molecular simulations 
showing that most of the uptake events of relatively small 
substrates by AcrB occur from the B monomer [147], and 
with all-atom MD simulations showing the entrance of sev-
eral solvent molecules into the DP from the cleft of the B 
monomer (Vargiu, Ruggerone & Nikaido, in preparation). 
Such a mechanism might also help to rationalize the binding 
of a dodecyl--D-maltoside molecule to the cleft of the B 
monomer (Figs. 4a, 4d) reported in Ref. [119]. Indeed, a 
maltoside molecule is quite stretched and has a molecular 
mass similar to taurocholic acid, which was also shown to 
bind the DP using a computational approach [120]. There-
fore, maltoside could in principle be transported from the 
access to the distal pocket without the need for significant 
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Fig. (9). Geometry of the essential residues D407, D408, K940, R971, and T978 in the transmembrane domain of the AcrB in the A (a), B 
(b), and C (c) monomers. The putative protonation state of these side chains in each monomer is indicated. Proton uptake is anticipated in the 
B monomer and is postulated to lead to the side chain reorientation of D407, K940 and R971. These conformational changes appear to be 
correlated to the coil-to-helix transition and the PN1/PC2 subdomain movement seen in the periplasmic pore domain during the B to C transi-
tion. Adapted from from Ref. [62]. 
 
rearrangements of the G-loop, as it has been found, although 
in the reverse direction, for the LMM inhibitor 1-
naphthylmethyl-piperazine (NMP, Fig. 2) in recent molecu-
lar dynamics simulations [120]. Moreover, as reported in the 
next section, despite for levofloxacin being a LMM com-
pound, its wide planar 4-ring structure could hinder its 
smooth diffusion through the AP-to-DP channel of the B 
monomer. Thus, the shape of each compound could be a 
parameter as important as its molecular mass in discerning 
among the interaction routes with AcrB.  
All substrates, of any mass and shape, should then be ex-
pelled from the DP towards the funnel in the TolC docking 
domain along the B to C step of the cycle. 
STRATEGIES TO OVERCOME EFFLUX-MEDIATED 
MDR 
Two main strategies are being investigated nowadays to 
overcome resistance mediated by bacterial efflux pumps [10, 
34, 67, 106, 116, 161-170]. The first strategy consists in by-
passing efflux pumps by improving the molecular design of 
existing antibiotics or by designing new ones, with the pur-
pose of altering the physico-chemical properties for recogni-
tion by efflux transporters. It is worth noticing that despite 
some new molecules less amenable for efflux have been 
produced, their design has been far from trivial. Examples 
are third and fourth generation quinolones, ketolides or gly-
cylcyclines (see e.g. Ref. [64] for a review). However, even 
for these new compounds resistance has been described very 
shortly after their deployment [48]. A second strategy con-
cerns the inactivation of efflux pumps, which is highly desir-
able for several reasons [162] as to:  
• Increase the intracellular concentration of antibiotics, 
thus enhancing the therapeutic index. 
• Decrease the intrinsic bacterial resistance to antibiotics, 
often caused by efflux pumps. 
• Reverse the acquired resistance associated with efflux 
pump overexpression. 
• Reduce the frequency of the emergence of highly resis-
tant mutant strains. Efflux pumps often provide the initial 
means for resistance, and causing survival of bacteria en-
able them to acquire other mechanisms of resistance like 
target-based mutations [163, 164, 166, 167, 169, 171]. 
• Prevent the export of virulence factors synthesized by 
microbes, thus inhibiting invasiveness and consequently 
the rise of bacterial infection [116, 172]. 
Inhibition of MDR pumps, specifically of RND pumps 
from Gram-negative bacteria, is a relatively new and dy-
namic field of intense research. In the last two decades a 
large number of reviews has been written on the subject, to 
which the reader is referred for a more comprehensive view 
[10, 67, 106, 116, 161-170]. While the following list of in-
hibitors describes several possible modes of inactivating 
efflux pumps, the focus here will be on RND efflux pumps, 
and in particular on pharmacological inhibitors interacting 
with E. coli AcrB for which structural information is avail-
able: 
1.  Inhibitors of proton motive force. Compounds that affect 
the energy gradient across the bacterial membrane such 
as carbonylcyanide m-chlorophenylhydrazone (CCCP), 
valinomycin, dinitrophenol (DNP), phenothiazines such 
as promethazine [165] are used to completely abolish the 
efflux of all toxic compounds [162, 166, 167]. Unfortu-
nately, these inhibitors have a very general mode of inac-
tivation, not only affecting efflux pumps but the entire 
energetics of the cell, including eukaryotic cells which 
makes them less attractive for clinical use [10, 116, 161, 
162]. 
2.  Biological Inhibitors. This class of inhibitors affects ef-
flux pump activity by blocking either the proteins them-
selves, e.g. with neutralizing antibodies, or by inactivat-
ing the genes encoding the pumps, by means of antisense 
oligonucleotides or small interfering RNAs, or other non-
traditional antisense molecules, which can interfere with 
transcription of the gene or translation of the encoding 
mRNA. The antisense approach has been shown to work 
14    Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 24 Ruggerone et al. 
for AcrAB efflux pump in E. coli and has also been pat-
ented [173, 174], but its application can be broadened to 
every pump of known sequence or to genes encoding 
proteins involved in the regulatory mechanism of pump 
expression (such as the Mar regulator [175]). 
3.  Pharmacological Inhibitors, also known as Efflux Pumps 
Inhibitors (EPIs). These are chemical compounds used: i) 
to interfere with the assembly or function of efflux 
pumps [176] (for instance, in the case of the tripartite 
RND systems, blocking of the OM channel may lead to 
the inhibition of efflux pump activity [177]); ii) in com-
bination therapy to increase the antibiotic concentration 
inside a pathogenic cell [10, 67, 116, 161, 162]. EPIs of 
this latter class act by competitive/non-competitive inhi-
bition of the pump, rendering antibiotics more effective, 
and might prevent accumulation of other resistance 
mechanisms over time. In addition to therapeutic use, 
specific EPIs can be employed for diagnostic purposes to 
evaluate the presence and contribution of the efflux 
mechanism in any given pathogen. 
Here we focus on the class of EPIs for use in combina-
tion therapy, summing up the ideal EPI characteristics [116, 
163]: 
1. The EPI should enhance the activity of multiple sub-
strates of the pump, and should not increase the activity 
of antibiotics that are not substrates, in order to guarantee 
its specific action against the target efflux pump. 
2. If the EPI should inhibit a specific pump of a given 
pathogen, cross-inactivation of other strains should be 
avoided. Moreover, the inhibitor should be free of any 
pharmacological activity on eukaryotic cells. This is true 
for PAN (vide infra), which is not recognized by eu-
karyotic (efflux) transporters [161]. 
3. The EPI should be structurally stable to ensure enhanced 
serum levels and cellular accumulation that potentiates its 
activity in intracellular infections. 
4. The EPI should have enhanced therapeutic index (or be 
atoxic) and pharmacokinetic profile to ensure maximum 
specificity and efficacy. In particular, the profile should 
be optimized in parallel to that of the antibiotic to be used 
in combination therapy. Toxicity is still a problem for 
several lead EPIs, and deserves special attention as EPIs 
might be used at high concentration in humans. 
5. The EPI itself should be ideally devoid of antibacterial 
activity as this could lead to development of resistance 
mechanisms against the EPI. Unfortunately, despite ef-
forts at matching this requirement, resistance induced by 
EPIs has already been reported in the literature ([178], 
and vide infra). 
In the following we describe some EPIs for which struc-
tural information of their interaction with AcrB, either from 
experimental or computational works, has been provided. 
Peptidomimetic EPIs 
These include the well-known PAN (Fig. 2) [179, 180] 
and its derivatives MC-02,595, MC-04,124, MC-510,051, 
MP 601,205 [164, 181], which were the first EPIs ever iden- 
 
tified and have been a valuable tool for drug discovery. 
PAN was identified by assaying an array of synthetic and 
natural compounds against Pseudomonas aeruginosa strains 
over-expressing three MDR efflux pumps (MexAB-OprM, 
MexCD-OprJ, MexEF-OprN) in the presence of levoflox-
acin. The magnitude of the potentiating effect was strongly 
dependent on the nature of the particular substrate, perhaps 
indicating that different antibiotics may have different bind-
ing sites on AcrB and that inhibition by PAN is binding 
site-specific [180].  
The attractiveness of PAN is based on its broad-
spectrum efflux pump inhibitory activity, necessary to have 
clinically significant impact on fluoroquinolones, which are 
extruded by many efflux pumps. Furthermore, a major bene-
fit of inhibition of multiple efflux pumps was a dramatic 
decrease in the frequency of emergence of P. aeruginosa 
strains with clinically relevant levels of resistance to fluoro-
quinolones [164, 180]. Resistant P. aeruginosa mutants with 
an MIC of 1 μg/ml for levofloxacin were isolated with a fre-
quency less than 10-11 (versus 10-7 in the absence of efflux 
pump inhibitors). These data are particularly important in 
view of results indicating that under stress conditions, such 
as those in acute clinical infections, there is an increased 
frequency of selection of hypermutable strains of P. aerugi-
nosa [182]. 
In addition to the inhibitory effect on the Mex pumps of 
P. aeruginosa described above, PAN has been validated 
against the AcrAB-TolC in Klebsiella pneumoniae, E. coli, 
Salmonella thyphimurium and Enterobacter aerogenes [183-
186], and in multiple homologous systems present in 
Acinetobacter baumannii [187, 188], Campylobacter jejuni 
and Campylobacter coli [189, 190]. 
Mechanistically, it has been proposed that PAN itself is 
an RND efflux pump substrate that acts as a competitive 
inhibitor by binding to the antibitoic binding pocket inside 
the RND component [164, 167, 191]. Consistent with this 
hypothesis are results of a recent docking survey of substrate 
and inhibitor binding sites within AcrB, showing that PAN 
binds indeed with the highest affinity to the DP of the trans-
porter [135]. Furthermore, on the basis the distinction be-
tween groove, cave, and mixed binders (see above), the 
authors furnished an explanation for the less efficient inhibi-
tion of ethidium and carbenicillin efflux (compared to 
levofloxacin) by PAN. According to their hypothesis, 
PAN is able to inhibit the efflux of levofloxacin by compe-
tition, because both compounds bind to the groove of the DP 
(although PAN was classified as mixed binder, it was 
bound mainly to the groove). In contrast, ethidium and car-
becinillin were classified as cave binders, so competition 
with PAN should not occur. 
However, in a follow-up study including docking and 
MD simulations [120] the distinction between groove and 
cave binders became blurred. In particular PAN changed 
significantly its mode of binding with respect to that found 
by docking, and moved towards the lower part of the DP. 
Moreover, this binding pose partly overlaps with the binding 
site of ethidium (Fig. 10; levofloxacin and carbenicillin were 
not included in the list of substrates studied in Ref. [120]), 
and also the calculated affinities of this compound and 
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Fig. (10). Comparison between the binding modes of PAN, ethidium (ETH), taurocholic acid (TAU), and 1-naphthylmethyl-piperazine 
(NMP) on the DP and AP (NMP’) of AcrB. Ligands are shown in colored spheres according to atom types (with nonpolar hydrogens re-
moved). Transparent surfaces indicate the DP (transparent red surface), the AP (green surface) pockets, and the PC1/PC2 subdomain cleft 
(orange surface). The G-loop is shown in gray. Residues that are within 3.5 Å from the ligand are shown as beads (red, green, orange, and 
yellow for those of DP, AP, PC1/PC2 subdomain cleft, and G-loop, respectively). Residues shared by the AP and DP are colored blue. For 
orientation, residues Q124 and Y758 defining the exit gate (far away from the ligand) are shown as gray beads. Adapted from Ref. [120]. 
 
PAN were similar. An interesting difference was found 
instead in the contribution to the stabilization of the ligand-
AcrB adducts from residues belonging to the DP (Tables 1 
and 2). Indeed, with ethidium (as well as with other sub-
strates not inhibiting the pump) these contributions were 
always significantly larger than with inhibitors such as 
PAN (Table 2). This finding could help explaining the inhi-
bition by PAN, if tight and specific interactions of sub-
strates with the DP (not achieved in the B monomer by 
PAN) are necessary to trigger functional rearrangements of 
AcrB. Moreover, PAN was found to straddle the G-loop 
separating the distal and proximal pockets, and whose flexi-
bility was shown to be important for the functioning of the 
pump [119, 121, 141], likely by regulating the smooth trans-
location of substrates between the two affinity sites along the 
AB step of the functional rotation. Thus, binding of PAN 
along the extrusion channel on top of the G-loop could effec-
tively block substrates while also hindering key conforma-
tional changes of the pump in some fashion.  
According to this hypothesis, we propose that ethidium 
and carbenicillin do not compete with PAN and their efflux 
is largely unaffected because these substrates may reach the 
DP by entering from the PC1/PC2 cleft of the B monomer 
itself, or because they have a larger affinity than PAN to 
this pocket. In agreement to this hypothesis are the recent 
findings by Yao et al. [147] and by some of the authors 
(Vargiu, Ruggerone & Nikaido, unpublished data), demon-
strating that access to the DP from monomer B could indeed 
be possible at least for LMM compounds and solvents. In 
this respect, despite for levofloxacin being a LMM com-
pound, its wide planar 4-ring structure could hinder its 
smooth diffusion through the AP-to-DP channel of the B 
monomer (Fig. 5). 
The binding of PAN to the AP was not investigated in 
any of the aforementioned studies, but it cannot be excluded 
that this inhibitor is binding to this access site. For instance, 
very strong inhibition of clarithromycin and rifampin [164] 
efflux is observed in the presence of PAN. These HMM 
antibiotics are supposed to bind with high affinity to the AP 
of the A monomer [119, 121]. On the other hand, efflux of 
linezolid or chloramphenicol, i.e. LMM compounds similar 
to ethidium and carbenicillin, is hardly affected in presence 
of PaN [163, 164]. Clearly, these observations are not ex-
clusively directing towards inhibition based on binding of 
the inhibitor to more than one site, since e.g. erythromycin is 
still expected to be transported via (part of the) DP in order 
to move towards the exit tunnel. Docking and MD studies 
are ongoing in our lab as to assess the likelihood of these 
additional mechanisms (Vargiu et al., unpublished data). 
The major problem with PAN is its toxicity towards 
human cells, which has prevented its clinical application 
[164]. For this reason significant efforts have been devoted 
to the optimization of PAN and its derivatives, which re-
sulted in the lead compound MC-04,124, exhibiting higher 
stability and reduced toxicity in experimental infections us-
ing an efflux pump overexpressing strain of P. aeruginosa 
[181]. 
Besides broad-spectrum inhibitors such as PAN, various 
peptidomimetics have been identified which are specific for 
each of the MexAB-OprM, MexCD-OprJ or MexEF-OprN 
tripartite pumps [163]. As mentioned above, while pump 
selective inhibitors may have limited therapeutic use, they 
may prove valuable for studying the contribution and preva-
lence of specific efflux pumps in clinical isolates of Gram-
positive and Gram-negative bacteria. This approach has re-
cently been successfully applied to P. aeruginosa and al-
lowed straightforward identification of strains over-
expressing efflux pumps [192]. 
Piperazines 
Several arylpiperazines have been shown to reverse 
MDR in bacteria overexpressing the AcrAB-TolC and 
AcrEF-TolC efflux systems. Some anthrylpiperazines and 
naphthylpiperazines, notably 1-naphthylmethyl-piperazine 
(NMP, Fig. 2), are among the most potent unsubstituted 
arylpiperazines, with a minimal effective concentration and a 
dose-dependent ability to increase the intracellular concen-
tration of several antibiotics, such as linezolid, chorampheni-
col, tetracycline, macrolides, and fluoroquinolones [193, 
194]. NMP seems to be effective in A. baumannii, several 
Enterobacteriaceae, but not in P. aeruginosa [187, 193-
195]. The list also includes trimethoprim and epinephrine 
[196], indole derivatives and quinolone derivatives [197]. 
Due to the serotonin agonist properties of these compounds, 
they are likely to be too toxic for use in humans. 
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Table 2.  Affinities of Selected Substrates and Inhibitors to AcrB, Together with Contributions to the Affinity from Residues Be-
longing to the DP, the AP and the G-Loop. The Hydrophobic Match is a Fraction Over the Whole Solvent Accessible Sur-
face [203], and the Free Energies (Standard Deviations in Parentheses) are in kcal/mol. From Ref. [120]. 
Compounds ETH PAbN TAU NMP 
Hydrophobic Match 0.90 0.68 0.78 0.77 
G (no Sconf) 31.0 (2.1) 30.1 (5.3) -23.3 (4.6) -22.3 (2.5) 
% GDP 41 29 52 20 
% GAP - - - - 
% GG-loop - - - 6 
 
As has been shown for PAN, NMP decreases MIC val-
ues specifically for some of the drugs used against an AcrB-
overproducing E. coli [193]. For instance, while the AcrB-
mediated efflux of chloramphenicol and of linezolid seems 
to be completely inhibited by NMP, clarithromycin efflux 
appears to be affected to a much lower extent. 
The mechanism of inhibition by NMP has not been un-
veiled yet. Some authors report that NMP is not a substrate 
of RND pumps [137], while recent computational studies 
found a good affinity to the B monomer of AcrB [120, 135]. 
In particular, in one study [120] it was shown that NMP in-
teracts and straddle the G-loop from either the DP or the AP 
side (Fig. 9 and Table 2). It was therefore suggested that, like 
PAN, the binding of NMP to a sub-pocket different than the 
DP or AP region might inactivate the pump by blocking the 
passage of antibiotics and hindering functional rearrange-
ments in the structure of AcrB [120].  
The analysis of available structural data suggests a possi-
ble mechanism for the different extent of NMP inhibition of 
AcrB-mediated efflux of chloramphenicol and linezolid on 
one side and clarithromycin on the other side. Indeed, it was 
found by computers simulations that NMP binds with high 
affinity to the lower part of the DP of the B monomer, partly 
overlapping with the binding site of chloramphenicol [120] 
(and probably that of linezolid). On the contrary, it is hard to 
hypothesize for NMP to have a larger affinity than 
clarithromycin towards the AP of the A monomer, where the 
latter antibiotic putatively binds first when sequestered by 
AcrB.  
Pyridopyrimidines 
A series of pyridopyrimidine derivatives were shown to 
be specific inhibitors of AcrAB-TolC and MexAB-OprM 
[198]. In contrast to PAN, they do not cause membrane 
dysfunction and have almost no antibiotic activity [199, 
200]. However, because these compounds do not inhibit 
MexXY–OprM, these are less useful as clinical drugs to tar-





Fig. 2) is an AcrB- and MexB-specific inhibitor and exhibits 
potent efficacy in vivo, is highly soluble, and shows a good 
safety profile in an acute toxicity assay [201]. In addition, 
D13-9001 is not exported by efflux pumps [200]. 
The structure of D13-9001 bound to AcrB and MexB (the 
first inhibitor-RND efflux pump structure) has been pub-
lished very recently [18]. D13-9001 binds to the DP of both 
AcrB and MexB, but unlike as with the co-crystal structures 
with doxorubicin or minocyclin, one part of the inhibitor 
molecule, the pyridopyrimidine ring moiety, inserts into a 
hydrophobic phenylalanine-rich cage branching off from the 
substrate-translocation channel (Fig. 11a). This cage is lined 
by residues F136, F178, F610, F615 and F628 in AcrB, and 
in addition also lined with F573 in MexB. In the case of 
MexY, the position of F178, lying in AcrB and MexB at the 
edge of the hydrophobic trap, is occupied by a voluminous 
W177 side chain, which prevents the binding of the inhibi-
tor. The authors of Ref. [18] also solved the structure of the 
F178W variant of AcrB, and revealed that the indolyl side 
chain of W178 hinders D13-9001 binding, as is the case for 
MexY. Moreover, by using microbiological and uptake as-
says they demonstrated that AcrBF178W is not inhibited by 
D13-9001, while MexYW177F is susceptible to this compound 
in a similar way as wt AcrB and MexB. Interestingly, the 
activity of D13-9001 on MexBF178W is similar to that on wt 
MexB, at odd with the findings for AcrB. This apparent dis-
crepancy was rationalized by the comparison of the X-ray 
structures of both mutants, showing that W178 protrudes 
into the narrow space of the hydrophobic trap in AcrB, but 
not in MexB. Indeed, the authors of Ref. [18] also resolved 
the structure of MexBF178W in complex with D13-9001, 
which was found within the hydrophobic trap as for the wt 
transporter. This work highlights how minimal changes in 
the conformation of the pocket drastically affect the affinity 
of a compound towards multi-functional sites of RND trans-
porters, and how this reflects directly on the biological activ-
ity of the substrate or inhibitor. 
On the basis of their findings, Nakashima et al. [18] sug-
gested the D13-9001 works by tightly binding to the hydro-
phobic trap and hindering the functional rotation mechanism 
of AcrB/MexB monomers. Consistently with this hypothesis, 
the inhibitor potentiates the activities of all of the antibiotics 
exported by AcrB/MexB, irrespective of their affinity to the 
deep or proximal access pockets. 
Interestingly, this observation resembles quite closely the 
hypothesis suggested in Ref. [202] for the impaired efflux of 
doxorubicin and many other compounds in F610A variants 
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Fig. (11). Binding of inhibitor D13-9001 in the DP of AcrB on basis of the structure of the complex published in Ref. [18] (a), compared to 
the binding of doxorubicin in the DP in the wild type (b; X-ray structure of PDB entry 4DX7[119]) and F610A variant of AcrB (c; from MD 
simulations in Ref. [202]). a) The inhibitor is shown in colored stick representation according to the atom type, while phenylalanine side 
chains F136, F178, F610, F615 and F628 are shown in thinner light purple sticks. The two yellow lines enclose schematically the extrusion 
channel and the yellow arrow indicates the direction of efflux. The blue line delimits the hydrophobic space accomodating the tert-butyl thia-
zolyl aminocarboxyl pyridopyrimidine (TAP) moiety of inhibitor D13-9001. b) Doxorubicin bound to the DP of AcrB Phenylalanines F178 
and F615 are within 3.5 A of the ligand (thick sticks). c) Doxorubicin sliding within the F-rich cage in the F610A variant. The position of the 
drug in wt AcrB is shown in thin gray sticks to highlight the reorientation and embedding of the antibiotic within the hydrophobic trap in the 
F610A variant. 
 
of AcrB [137, 138]. In that report several MD simulations of 
doxorubicin in complex with the AcrBF610A were performed, 
and the binding to the DP was compared between the wt and 
mutant protein. It was found that, compared to the binding in 
the wt AcrB (Fig. 11b, notice that only F178 and F615 are 
within 3.5 Å of the ligand) the F610A variant allowed slid-
ing of doxorubicin by 4/5 Å within a pocket lined by F136, 
F178, F615 and F628, now interacting more tightly with the 
antibiotic (Fig. 11c). In Ref. [202] it was suggested already 
that the inhibitory effect associated to the F610A mutation 
was likely due to the increased dwelling time and affinity of 
substrates in the binding pocket of the AcrB variant. Thus, 
the mutation can lead to a competitive inhibition by either 
hindering conformational changes in the pump or interfering 
with the extrusion of substrates due to the observed binding 
to the remote hydrophobic pocket area, which can normally 
not be accessed due to steric hindrance of F610. 
SUMMARY AND FUTURE DIRECTIONS 
Since the discovery of the first bacterial multi-drug 
transporter, the research in the field of efflux pumps has 
made great strides. Biological, biochemical, structural and 
computational, studies have revealed many aspects of the 
mechanisms behind multi-drug recognition and extrusion. In 
this review, we summarized the main outcomes from these 
studies focusing on the best known RND transporter AcrB, 
by outlining the key steps of substrate uptake, recognition 
and extrusion catalyzed by this drug transporter.  
Despite the advances outlined in the review, dissecting 
the molecular and conformational steps that regulate trans-
port of substrates by these pumps remains a very challenging 
task, which is increasingly needed for a complete under-
standing of mechanistic and structure/function relationship 
of the drug efflux process. Regarding the structural proper-
ties, new crystallographic studies and/or more accurate mod-
eling techniques are needed in order to achieve a full atomic 
picture of the entire tripartite complexes, which is required to 
understand the functional dynamics of this machinery in re-
lation to substrate efflux. In turn, such knowledge will allow 
for a clearer interpretation of biological experiments, i.e. it 
will link experiments on the molecular level (including sin-
gle molecule assays) to those conducted on the intact cell 
(i.e.containing an ensemble of efflux pumps). This informa-
tion can be directly transferred to applied research aimed at 
the development of inhibitors against efflux transporters or 
of antibiotics less susceptible to efflux in Gram-negative 
bacteria. 
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